Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides

Elizabeth J. Ackermann, Shuling Guo, Merrill Benson, Sheri Booten, Sue Freier, Steven G. Hughes, Tae Won Kim, T. Jesse Kwoh, John Matson, Dan Norris, Rosie Yu, Andy Watt, Brett P. Monia

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease that results from the deposition of misfolded transthyretin (TTR) protein from the plasma into tissues as amyloid fibrils, leading to polyneuropathy and cardiomyopathy. IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. The activity of IONIS-TTRRx to decrease TTR protein levels was studied in transgenic mice bearing the Ile84Ser human TTR mutant, in cynomolgus monkeys and in healthy human volunteers. Robust (>80%) reductions of plasma TTR protein were obtained in all three species treated with IONIS-TTRRx, which in mice and monkeys was associated with substantial reductions in hepatic TTR RNA levels. These effects were dose-dependent and lasted for weeks post-dosing. In a Phase 1 healthy volunteer study, treatment with IONIS-TTRRx for four weeks was well tolerated without any remarkable safety issues. TTR protein reductions up to 96% in plasma were observed. These nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAmyloid
DOIs
StateAccepted/In press - Jun 17 2016

Fingerprint

Prealbumin
Antisense Oligonucleotides
Haplorhini
Amyloidosis
Blood Proteins
Healthy Volunteers
RNA
Proteins
Macaca fascicularis
Polyneuropathies
Rare Diseases
Cardiomyopathies
Amyloid
Transgenic Mice
Safety
Liver

Keywords

  • Amyloidosis
  • ATTR
  • FAC
  • familial
  • FAP

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. / Ackermann, Elizabeth J.; Guo, Shuling; Benson, Merrill; Booten, Sheri; Freier, Sue; Hughes, Steven G.; Kim, Tae Won; Jesse Kwoh, T.; Matson, John; Norris, Dan; Yu, Rosie; Watt, Andy; Monia, Brett P.

In: Amyloid, 17.06.2016, p. 1-10.

Research output: Contribution to journalArticle

Ackermann, EJ, Guo, S, Benson, M, Booten, S, Freier, S, Hughes, SG, Kim, TW, Jesse Kwoh, T, Matson, J, Norris, D, Yu, R, Watt, A & Monia, BP 2016, 'Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides', Amyloid, pp. 1-10. https://doi.org/10.1080/13506129.2016.1191458
Ackermann, Elizabeth J. ; Guo, Shuling ; Benson, Merrill ; Booten, Sheri ; Freier, Sue ; Hughes, Steven G. ; Kim, Tae Won ; Jesse Kwoh, T. ; Matson, John ; Norris, Dan ; Yu, Rosie ; Watt, Andy ; Monia, Brett P. / Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. In: Amyloid. 2016 ; pp. 1-10.
@article{9abcb69a76fa4f4fbe9a7e4587385ed4,
title = "Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides",
abstract = "Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease that results from the deposition of misfolded transthyretin (TTR) protein from the plasma into tissues as amyloid fibrils, leading to polyneuropathy and cardiomyopathy. IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. The activity of IONIS-TTRRx to decrease TTR protein levels was studied in transgenic mice bearing the Ile84Ser human TTR mutant, in cynomolgus monkeys and in healthy human volunteers. Robust (>80{\%}) reductions of plasma TTR protein were obtained in all three species treated with IONIS-TTRRx, which in mice and monkeys was associated with substantial reductions in hepatic TTR RNA levels. These effects were dose-dependent and lasted for weeks post-dosing. In a Phase 1 healthy volunteer study, treatment with IONIS-TTRRx for four weeks was well tolerated without any remarkable safety issues. TTR protein reductions up to 96{\%} in plasma were observed. These nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis.",
keywords = "Amyloidosis, ATTR, FAC, familial, FAP",
author = "Ackermann, {Elizabeth J.} and Shuling Guo and Merrill Benson and Sheri Booten and Sue Freier and Hughes, {Steven G.} and Kim, {Tae Won} and {Jesse Kwoh}, T. and John Matson and Dan Norris and Rosie Yu and Andy Watt and Monia, {Brett P.}",
year = "2016",
month = "6",
day = "17",
doi = "10.1080/13506129.2016.1191458",
language = "English (US)",
pages = "1--10",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides

AU - Ackermann, Elizabeth J.

AU - Guo, Shuling

AU - Benson, Merrill

AU - Booten, Sheri

AU - Freier, Sue

AU - Hughes, Steven G.

AU - Kim, Tae Won

AU - Jesse Kwoh, T.

AU - Matson, John

AU - Norris, Dan

AU - Yu, Rosie

AU - Watt, Andy

AU - Monia, Brett P.

PY - 2016/6/17

Y1 - 2016/6/17

N2 - Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease that results from the deposition of misfolded transthyretin (TTR) protein from the plasma into tissues as amyloid fibrils, leading to polyneuropathy and cardiomyopathy. IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. The activity of IONIS-TTRRx to decrease TTR protein levels was studied in transgenic mice bearing the Ile84Ser human TTR mutant, in cynomolgus monkeys and in healthy human volunteers. Robust (>80%) reductions of plasma TTR protein were obtained in all three species treated with IONIS-TTRRx, which in mice and monkeys was associated with substantial reductions in hepatic TTR RNA levels. These effects were dose-dependent and lasted for weeks post-dosing. In a Phase 1 healthy volunteer study, treatment with IONIS-TTRRx for four weeks was well tolerated without any remarkable safety issues. TTR protein reductions up to 96% in plasma were observed. These nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis.

AB - Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease that results from the deposition of misfolded transthyretin (TTR) protein from the plasma into tissues as amyloid fibrils, leading to polyneuropathy and cardiomyopathy. IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. The activity of IONIS-TTRRx to decrease TTR protein levels was studied in transgenic mice bearing the Ile84Ser human TTR mutant, in cynomolgus monkeys and in healthy human volunteers. Robust (>80%) reductions of plasma TTR protein were obtained in all three species treated with IONIS-TTRRx, which in mice and monkeys was associated with substantial reductions in hepatic TTR RNA levels. These effects were dose-dependent and lasted for weeks post-dosing. In a Phase 1 healthy volunteer study, treatment with IONIS-TTRRx for four weeks was well tolerated without any remarkable safety issues. TTR protein reductions up to 96% in plasma were observed. These nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis.

KW - Amyloidosis

KW - ATTR

KW - FAC

KW - familial

KW - FAP

UR - http://www.scopus.com/inward/record.url?scp=84976444883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976444883&partnerID=8YFLogxK

U2 - 10.1080/13506129.2016.1191458

DO - 10.1080/13506129.2016.1191458

M3 - Article

C2 - 27355239

AN - SCOPUS:84976444883

SP - 1

EP - 10

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

ER -